--- title: "New York State Common Retirement Fund Has $12.05 Million Stake in Bruker Corporation $BRKR" description: "New York State Common Retirement Fund increased its stake in Bruker Corporation (NASDAQ:BRKR) by 52.5% in Q3, owning 370,797 shares valued at $12.05 million. Other investors also adjusted their holdin" type: "news" locale: "en" url: "https://longbridge.com/en/news/274635149.md" published_at: "2026-02-03T10:05:28.000Z" --- # New York State Common Retirement Fund Has $12.05 Million Stake in Bruker Corporation $BRKR > New York State Common Retirement Fund increased its stake in Bruker Corporation (NASDAQ:BRKR) by 52.5% in Q3, owning 370,797 shares valued at $12.05 million. Other investors also adjusted their holdings, with significant increases from AQR Capital Management and Orbis Allan Gray. Bruker shares recently opened at $43.75, with a market cap of $6.65 billion. The company reported Q3 earnings of $0.45 per share, exceeding estimates, but revenue declined 0.5% year-over-year. Analysts have varied ratings and price targets for Bruker, reflecting mixed sentiments on its stock performance. New York State Common Retirement Fund raised its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 52.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 370,797 shares of the medical research company's stock after buying an additional 127,698 shares during the period. New York State Common Retirement Fund owned 0.24% of Bruker worth $12,047,000 at the end of the most recent reporting period. A number of other large investors also recently modified their holdings of BRKR. Orbis Allan Gray Ltd acquired a new stake in shares of Bruker in the second quarter valued at about $192,735,000. AQR Capital Management LLC increased its position in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Bruker during the 2nd quarter worth approximately $62,032,000. Norges Bank acquired a new stake in shares of Bruker in the 2nd quarter valued at approximately $44,459,000. Finally, Vaughan Nelson Investment Management L.P. grew its stake in shares of Bruker by 61.6% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company's stock valued at $67,909,000 after buying an additional 796,510 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds. ## Bruker Stock Down 1.2% Shares of BRKR opened at $43.75 on Tuesday. The firm has a market cap of $6.65 billion, a P/E ratio of -273.44, a price-to-earnings-growth ratio of 5.82 and a beta of 1.19. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $57.92. The firm's 50-day simple moving average is $48.25 and its 200 day simple moving average is $40.45. Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The company had revenue of $860.50 million during the quarter, compared to analysts' expectations of $847.40 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The business's revenue was down .5% on a year-over-year basis. On average, analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year. ## Insiders Place Their Bets In other Bruker news, Director John A. Ornell sold 6,233 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director owned 35,212 shares in the company, valued at $1,373,268. This trade represents a 15.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the sale, the vice president directly owned 128,443 shares of the company's stock, valued at $7,064,365. This represents a 5.17% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 15,233 shares of company stock worth $726,487. Insiders own 27.30% of the company's stock. ## Wall Street Analyst Weigh In A number of analysts have commented on BRKR shares. UBS Group increased their price target on shares of Bruker from $40.00 to $43.00 and gave the company a "neutral" rating in a research note on Tuesday, November 4th. JPMorgan Chase & Co. raised their target price on shares of Bruker from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Monday, December 15th. Wolfe Research upgraded Bruker from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a report on Wednesday, December 10th. TD Cowen restated a "hold" rating on shares of Bruker in a research note on Wednesday, January 7th. Finally, Zacks Research raised Bruker from a "strong sell" rating to a "hold" rating in a research report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $53.71. **Get Our Latest Report on Bruker** ## Bruker Company Profile (Free Report) Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories. Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners. In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance. ## Read More - Five stocks we like better than Bruker - The day the gold market broke - Forget AI, This Will Be the Next Big Tech Breakthrough - ~$1.5T SpaceX IPO: Pre-IPO Opportunity - Gold’s getting scarce. - End of America Update *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Bruker Right Now? Before you consider Bruker, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list. While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BRKR.US - Bruker](https://longbridge.com/en/quote/BRKR.US.md) - [IHI.US - iShares US Medical Devices](https://longbridge.com/en/quote/IHI.US.md) - [XHE.US - SPDR S&P Health Equip](https://longbridge.com/en/quote/XHE.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [BRKRP.US - Bruker Corp Pref Shares BRKRP 6.375 09/01/2028](https://longbridge.com/en/quote/BRKRP.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 这些分析师在布鲁克公布第四季度业绩后下调了他们的预测 | 布鲁克公司（NASDAQ:BRKR）公布了混合的第四季度业绩，收益为每股 59 美分，低于预期的 65 美分，但销售额为 9.772 亿美元，超过了预期的 9.608 亿美元。该公司预计 2026 财年的调整后每股收益为 2.10 至 2. | [Link](https://longbridge.com/en/news/275927262.md) | | Envestnet 资产管理公司减少了其在爱德华生命科学公司$EW 的股票持仓 | Envestnet Asset Management Inc. 在第三季度减少了对爱德华生命科学公司的持股比例，降幅为 23.1%，目前持有 261,587 股，市值为 2034 万美元。其他机构投资者也调整了他们的持仓。内部交易方面，副总 | [Link](https://longbridge.com/en/news/275999995.md) | | Johnson Investment Counsel Inc. 减持了 Zimmer Biomet Holdings, Inc. $ZBH 的股票 | Johnson Investment Counsel Inc. 在第三季度减少了对 Zimmer Biomet Holdings, Inc. 的持股比例，下降了 38.3%，目前持有 28,930 股，价值 285 万美元。其他机构投资者也 | [Link](https://longbridge.com/en/news/275752492.md) | | Assetmark Inc.增加了对碧迪医疗公司（Becton, Dickinson and Company）的持股 $BDX | Assetmark Inc. 在第三季度将其在碧迪医疗（NYSE:BDX）的持股增加了 49.5%，目前拥有 225,967 股，价值 4229 万美元。其他机构投资者也调整了他们的持股，Brighton Jones LLC 将其持股增加了 | [Link](https://longbridge.com/en/news/275971326.md) | | 布鲁克公司第四季度收入因生物制药市场的复苏而超出预期 | 布鲁克公司报告 2025 年第四季度收入为 9.772 亿美元，超出分析师预期的 9.6083 亿美元，尽管同比增长持平。然而，调整后的每股收益为 0.59 美元，低于 0.65 美元的预期。公司预计 2026 财年的收入增长为 4% 至 | [Link](https://longbridge.com/en/news/275752855.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.